ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · IEX Real-Time Price · USD
17.12
+0.04 (0.23%)
May 3, 2024, 11:57 AM EDT - Market open
ACADIA Pharmaceuticals Employees
ACADIA Pharmaceuticals had 598 employees on December 31, 2023. The number of employees increased by 85 or 16.57% compared to the previous year.
Employees
598
Change (1Y)
85
Growth (1Y)
16.57%
Revenue / Employee
$1,214,778
Profits / Employee
-$102,485
Market Cap
2.82B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 598 | 85 | 16.57% |
Dec 31, 2022 | 513 | -1 | -0.19% |
Dec 31, 2021 | 514 | -87 | -14.48% |
Dec 31, 2020 | 601 | 98 | 19.48% |
Dec 31, 2019 | 503 | 73 | 16.98% |
Dec 31, 2018 | 430 | 5 | 1.18% |
Dec 31, 2017 | 425 | 55 | 14.86% |
Dec 31, 2016 | 370 | 210 | 131.25% |
Dec 31, 2015 | 160 | 63 | 64.95% |
Dec 31, 2014 | 97 | 49 | 102.08% |
Dec 31, 2013 | 48 | 22 | 84.62% |
Dec 31, 2012 | 26 | 2 | 8.33% |
Dec 31, 2011 | 24 | -3 | -11.11% |
Dec 31, 2010 | 27 | 0 | - |
Dec 31, 2009 | 27 | -36 | -57.14% |
Dec 31, 2008 | 63 | -80 | -55.94% |
Dec 31, 2007 | 143 | 5 | 3.62% |
Dec 31, 2006 | 138 | 26 | 23.21% |
Dec 31, 2005 | 112 | 11 | 10.89% |
Dec 31, 2004 | 101 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Azenta | 3,500 |
Certara | 1,391 |
Olink Holding AB (publ) | 707 |
GoodRx Holdings | 694 |
Arrowhead Pharmaceuticals | 525 |
Immunocore Holdings | 497 |
Merus | 229 |
Arcellx | 130 |
ACAD News
- 3 days ago - Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship - Business Wire
- 8 days ago - Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 - Business Wire
- 11 days ago - Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada - Business Wire
- 13 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting - Business Wire
- 4 weeks ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 4 weeks ago - Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire